Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Integrins: Integrating the Biology and Therapy of Cell-cell Interactions.

Pandolfi F, Franza L, Altamura S, Mandolini C, Cianci R, Ansari A, Kurnick JT.

Clin Ther. 2017 Dec;39(12):2420-2436. doi: 10.1016/j.clinthera.2017.11.002. Epub 2017 Dec 6. Review.

PMID:
29203050
2.

Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.

Haggerty TJ, Dunn IS, Rose LB, Newton EE, Pandolfi F, Kurnick JT.

PLoS One. 2014 Dec 12;9(12):e114506. doi: 10.1371/journal.pone.0114506. eCollection 2014.

3.

A screening assay to identify agents that enhance T-cell recognition of human melanomas.

Haggerty TJ, Dunn IS, Rose LB, Newton EE, Kurnick JT.

Assay Drug Dev Technol. 2012 Apr;10(2):187-201. doi: 10.1089/adt.2011.0379. Epub 2011 Nov 15.

4.

Skewed T-cell receptor repertoire: more than a marker of malignancy, a tool to dissect the immunopathology of inflammatory diseases.

Pandolfi F, Cianci R, Casciano F, Pagliari D, De Pasquale T, Landolfi R, Di Sante G, Kurnick JT, Ria F.

J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):153-61.

PMID:
21880203
5.

Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.

Haggerty TJ, Dunn IS, Rose LB, Newton EE, Martin S, Riley JL, Kurnick JT.

Cancer Immunol Immunother. 2011 Jan;60(1):133-44. doi: 10.1007/s00262-010-0926-x. Epub 2010 Oct 30.

6.

Strategies to overcome obstacles to successful immunotherapy of melanoma.

Pandolfi F, Cianci R, Lolli S, Dunn IS, Newton EE, Haggerty TJ, Boyle LA, Kurnick JT.

Int J Immunopathol Pharmacol. 2008 Jul-Sep;21(3):493-500. Review.

7.

Enhancement of human melanoma antigen expression by IFN-beta.

Dunn IS, Haggerty TJ, Kono M, Durda PJ, Butera D, Macdonald DB, Benson EM, Rose LB, Kurnick JT.

J Immunol. 2007 Aug 15;179(4):2134-42.

8.

Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.

Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, Benson EM, Kurnick JT.

Mol Cancer Res. 2006 Oct;4(10):779-92.

9.

Induction of "antigen silencing" in melanomas by oncostatin M: down-modulation of melanocyte antigen expression.

Durda PJ, Dunn IS, Rose LB, Butera D, Benson EM, Pandolfi F, Kurnick JT.

Mol Cancer Res. 2003 Apr;1(6):411-9.

10.

A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.

Kurnick JT, Ramirez-Montagut T, Boyle LA, Andrews DM, Pandolfi F, Durda PJ, Butera D, Dunn IS, Benson EM, Gobin SJ, van den Elsen PJ.

J Immunol. 2001 Aug 1;167(3):1204-11.

11.

Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Hellman J, Loiselle PM, Tehan MM, Allaire JE, Boyle LA, Kurnick JT, Andrews DM, Sik Kim K, Warren HS.

Infect Immun. 2000 May;68(5):2566-72.

12.

Release of gram-negative outer-membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to Escherichia coli J5.

Hellman J, Loiselle PM, Zanzot EM, Allaire JE, Tehan MM, Boyle LA, Kurnick JT, Warren HS.

J Infect Dis. 2000 Mar;181(3):1034-43.

PMID:
10720528
13.

Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.

Ramirez-Montagut T, Andrews DM, Ihara A, Pervaiz S, Pandolfi F, Van Den Elsen PJ, Waitkus R, Boyle LA, Hishii M, Kurnick JT.

Clin Exp Immunol. 2000 Jan;119(1):11-8.

14.

Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.

Hishii M, Kurnick JT, Ramirez-Montagut T, Pandolfi F.

Clin Exp Immunol. 1999 Jun;116(3):388-94.

15.

Oligoclonality of Vdelta1 and Vdelta2 cells in human peripheral blood mononuclear cells: TCR selection is not altered by stimulation with gram-negative bacteria.

Shen J, Andrews DM, Pandolfi F, Boyle LA, Kersten CM, Blatman RN, Kurnick JT.

J Immunol. 1998 Mar 15;160(6):3048-55.

16.

Antiserum against Escherichia coli J5 contains antibodies reactive with outer membrane proteins of heterologous gram-negative bacteria.

Hellman J, Zanzot EM, Loiselle PM, Amato SF, Black KM, Ge Y, Kurnick JT, Warren HS.

J Infect Dis. 1997 Nov;176(5):1260-8.

PMID:
9359727
17.

T cell receptor usage by HLA-DR3-specific T cell clones isolated from a renal allograft.

Kumagai-Braesch M, Boyle L, van den Elsen P, Kurnick JT.

Transpl Immunol. 1997 Jun;5(2):129-35.

PMID:
9269035
18.

In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.

Hishii M, Andrews D, Boyle LA, Wong JT, Pandolfi F, van den Elsen PJ, Kurnick JT.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1378-83.

19.
20.

T cell receptors in rheumatoid arthritis.

Struyk L, Hawes GE, Chatila MK, Breedveld FC, Kurnick JT, van den Elsen PJ.

Arthritis Rheum. 1995 May;38(5):577-89. Review. No abstract available.

PMID:
7748212
21.

Responses of human T cells to dominant discrete protein antigens of Escherichia coli and Pseudomonas aeruginosa.

Kersten CM, McCluskey RT, Shaw Warren H, Kurnick JT.

Scand J Immunol. 1994 Aug;40(2):151-7.

PMID:
7519358
22.

Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.

Kalams SA, Johnson RP, Trocha AK, Dynan MJ, Ngo HS, D'Aquila RT, Kurnick JT, Walker BD.

J Exp Med. 1994 Apr 1;179(4):1261-71.

23.
24.

T lymphocyte responses to antigens of gram-negative bacteria in pyelonephritis.

Wilz SW, Kurnick JT, Pandolfi F, Rubin RH, Warren HS, Goldstein R, Kersten CM, McCluskey RT.

Clin Immunol Immunopathol. 1993 Oct;69(1):36-42.

PMID:
8403542
25.

Phenotypic characteristics of lymphoid populations of middle gestation human fetal liver, spleen and thymus.

Erbach GT, Semple JP, Osathanondh R, Kurnick JT.

J Reprod Immunol. 1993 Sep;25(1):81-8.

PMID:
8271241
26.

Phenotypic characteristics of lymphocyte populations isolated from middle gestation human placenta.

Erbach GT, Semple JP, Milford E, Goguen J, Osathanondh R, Kurnick JT.

J Reprod Immunol. 1993 Sep;25(1):1-13.

PMID:
8271236
27.

T-cell receptor V-gene usage in synovial fluid lymphocytes of patients with chronic arthritis.

Struyk L, Kurnick JT, Hawes GE, van Laar JM, Schipper R, Oksenberg JR, Steinman L, de Vries RR, Breedveld FC, van den Elsen P.

Hum Immunol. 1993 Aug;37(4):237-51.

PMID:
8300409
28.

Fibroblast-derived factors preserve viability in vitro of mononuclear cells isolated from subjects with HIV-1 infection.

Pandolfi F, Oliva A, Sacco G, Polidori V, Liberatore D, Mezzaroma I, Giovannetti A, Kurnick JT, Aiuti F.

AIDS. 1993 Mar;7(3):323-9.

PMID:
8471193
29.
30.

Dominant rearrangements among human tumor-infiltrating lymphocytes. Analysis of T-cells derived from 32 patients with melanoma, lung, and renal cell carcinoma.

Bennett WT, Pandolfi F, Grove BH, Hawes GE, Boyle LA, Kradin RL, Kurnick JT.

Cancer. 1992 May 1;69(9):2379-84.

PMID:
1314129
31.

Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes.

Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, Kurnick JT.

Cancer. 1992 Mar 1;69(5):1165-73.

PMID:
1739916
32.

Cytotoxic activity of graft-infiltrating lymphocytes correlates with cellular rejection in cardiac transplant patients.

Frisman DM, Fallon JT, Hurwitz AA, Dec WG, Kurnick JT.

Hum Immunol. 1991 Dec;32(4):241-5.

PMID:
1686025
33.

Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.

Kurnick JT, Kradin RL.

Allergol Immunopathol (Madr). 1991 Sep-Oct;19(5):209-14. Review. No abstract available.

PMID:
1811418
34.

Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.

Pandolfi F, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni-Celli S.

Cancer Res. 1991 Jun 15;51(12):3164-70.

35.

Fibroblasts mediate T cell survival: a proposed mechanism for retention of primed T cells.

Scott S, Pandolfi F, Kurnick JT.

J Exp Med. 1990 Dec 1;172(6):1873-6.

36.

Clonal dominance among synovial tissue-infiltrating lymphocytes in arthritis.

Chatila MK, Pandolfi F, Stamenkovich I, Kurnick JT.

Hum Immunol. 1990 Jun;28(2):252-7.

PMID:
2351572
37.

Clonal analysis of graft-infiltrating lymphocytes from renal and cardiac biopsies. Dominant rearrangements of TcR beta genes and persistence of dominant rearrangements in serial biopsies.

Frisman DM, Hurwitz AA, Bennett WT, Boyle LA, Fallon JT, Dec GW, Colvin RB, Kurnick JT.

Hum Immunol. 1990 Jun;28(2):208-15.

PMID:
2141012
38.
39.
40.

Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.

Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL.

J Immunol. 1989 Nov 15;143(10):3404-11.

PMID:
2509557
41.

Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma.

Dubinett SM, Kurnick JT, Kradin RL.

Am J Respir Cell Mol Biol. 1989 Nov;1(5):361-9.

PMID:
2517774
42.

Characteristics of lymphocytes cultured from murine viral myocarditis specimens: a preliminary and technical report.

Kishimoto C, Kurnick JT, Fallon JT, Crumpacker CS, Abelmann WH.

J Am Coll Cardiol. 1989 Sep;14(3):799-802.

43.

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.

Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, et al.

Lancet. 1989 Mar 18;1(8638):577-80.

PMID:
2564111
44.

Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens.

Kradin RL, Kurnick JT, Preffer FI, Dubinett SM, Dickersin GR, Pinto C.

Clin Immunol Immunopathol. 1989 Feb;50(2):184-95.

PMID:
2783665
45.

Escherichia coli-specific T lymphocytes in experimental pyelonephritis.

Kurnick JT, McCluskey RT, Bhan AK, Wright KA, Wilkinson R, Rubin RH.

J Immunol. 1988 Nov 1;141(9):3220-6.

PMID:
2459249
46.

T lymphocyte infiltrates in inflammatory synovia are oligoclonal.

Stamenkovic I, Stegagno M, Wright KA, Krane SM, Amento EP, Colvin RB, Duquesnoy RJ, Kurnick JT.

Transplant Proc. 1988 Apr;20(2):315-9. No abstract available.

PMID:
2966470
47.

Clonal dominance among T-lymphocyte infiltrates in arthritis.

Stamenkovic I, Stegagno M, Wright KA, Krane SM, Amento EP, Colvin RB, Duquesnoy RJ, Kurnick JT.

Proc Natl Acad Sci U S A. 1988 Feb;85(4):1179-83.

48.

T lymphocytes in synovia of patients with rheumatoid arthritis.

Stamenkovic I, Stegagno M, Krane SM, Kurnick JT.

Springer Semin Immunopathol. 1988;10(2-3):169-80. Review. No abstract available.

PMID:
3055376
49.

The poor accessory cell function of macrophages in the rat may reflect their inability to form clusters with T cells.

Kradin RL, McCarthy KM, Dailey CI, Burdeshaw A, Kurnick JT, Schneeberger EE.

Clin Immunol Immunopathol. 1987 Sep;44(3):348-63.

PMID:
3497747
50.

Factor XIII A is synthesized and expressed on the surface of U937 cells and alveolar macrophages.

Kradin RL, Lynch GW, Kurnick JT, Erikson M, Colvin RB, McDonagh J.

Blood. 1987 Mar;69(3):778-85.

PMID:
2880614

Supplemental Content

Loading ...
Support Center